Timothy Looney, PhD – Senior Director, Immunology and Bioinformatics at Singular Genomics By: Timothy Looney, PhD Date: 9/12/2023 The topic at hand revolves around “Immune-Related Adverse Events (IRAEs)” in the context of cancer treatment using “Immune Checkpoint Inhibitors (ICIs).” Timothy Looney, a prominent researcher with a PhD, discusses the significance of IRAEs in cancer immunotherapy. IRAEs are adverse events that occur when therapeutic agents like ICIs activate T cells, causing them to mistakenly target healthy tissues, leading to damage or destruction. These events, which can range from mild to life-threatening, are a major concern in cancer immunotherapy due to the…
Author: Editor
The interview with Jill O’Donnell-Tormey, PhD, delves into the vital topic of cancer immunotherapy and research, emphasizing the transformative potential of harnessing the human immune system to combat various forms of cancer. Throughout the conversation, O’Donnell-Tormey provides valuable insights and perspectives on key areas of focus within the field. Here are some direct quotes from her on these topics:On the mission of the Cancer Research Institute (CRI):”We are a non-profit organization that’s been around for 70 years with the singular view that your immune system could be harnessed as a way to treat, control, and potentially cure all cancers.”On the…
In the interview, Susan Pandya, MD, Vice President of Clinical Development at Servier Pharmaceuticals, discusses the pivotal FDA acceptance and priority review for TIBSOVO in the treatment of IDH1-mutated relapsed or refractory myelodysplastic syndromes (MDS). The acceptance marks a significant milestone in advancing targeted therapies for patients facing limited options in this challenging disease context.TIBSOVO’s clinical data submission showcased remarkable results, with complete remissions achieved in approximately 40% of patients and an overall response rate of 83.3% among those with relapsed or refractory IDH1-mutated MDS. These outcomes far exceed existing treatment options, underscoring TIBSOVO’s potential as a transformative therapy for…
Marwan Fakih, MD – City of Hope – FDA Approval of LONSURF in combination with Bevacizumab The FDA approval of Lonsurf plus Bevacizumab represents a significant breakthrough in the treatment of metastatic colorectal cancer. This combination therapy offers new hope for patients who have previously exhausted their treatment options, providing substantial improvements in both overall survival and progression-free survival. The clinical trial results from the Sunlight trial have solidified Lonsurf plus Bevacizumab as the standard third-line treatment for metastatic colorectal cancer, with potential implications for future research and control arms in clinical trials. Physicians are encouraged to consider this combination…
Joshua Brody, MD – Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount SinaiHess Center for Science and Medicine – Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming What is the role of primed CD8 T-cells in cancer immunotherapies, and how does their recognition of tumor antigens presented on MHC-I contribute to the antitumor response?What are the critical factors in loading dendritic cells (DC) with tumor antigens, and how can we optimize this process to enhance antitumor T-cell responses?Can you explain the advantages and limitations of using neoantigen vaccines based on individualized tumor exome and RNA…
In the interview with Allen Wilbanks of OncologyTube, Peter Langmuir, the Vice President of Oncology Drug Development at Incyte, discussed the Agave 201 trial and its outcomes. Mr. Langmuir explained, “The Agave 201 trial was a clinical trial in patients with chronic GVHD, looking at the drug axatilimab, a monoclonal antibody against the CSF1 receptor. That was originally developed by our partners at syntax. And this trial was initiated by them to do two things. First of all, one was to try to identify the most appropriate dose of axatilimab to use in these patients based on both safety and…
The recent approval by the Food and Drug Administration (FDA) of mirvetuximab soravtansine-gynx (Elahere) marks a significant advancement in the treatment landscape for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. This article aims to provide oncologists with a comprehensive overview of the efficacy, safety profile, and prescribing considerations associated with this novel therapeutic agent. Efficacy Evaluation: Study 0416 Mirvetuximab soravtansine-gynx’s (Elahere) approval was based on data from Study 0416 (MIRASOL), a pivotal multicenter trial involving 453 patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patients enrolled in the study had…
Mark Schoenberg, MD- UrologyGenitourinary (GU) CancerBladder Cancer-The Montefiore Medical Center and The Albert Einstein College of Medicine at UroGen Pharma What is UGN-102, and what is its potential role as the first non-surgical therapy for LG-IR-NMIBC? Could you explain the primary endpoints achieved in both the ATLAS and ENVISION clinical trials for UGN-102? In the ATLAS trial, UGN-102 showed a 55% reduction in the risk of recurrence, progression, or death compared to TURBT. How significant is this finding for patients with LG-IR-NMIBC? What was the complete response rate at three months observed in the ENVISION trial, and how does it…
Elizabeth Brem , MD discusses the design and outcomes of the study referred to as 1826. The study aimed to enhance outcomes and address toxicities in Hodgkin lymphoma treatment. Nivolumab’s potential benefits in comparison to brentuximab within the AVD backbone were explored. Additionally, Brem highlights the collaborative nature of the study, involving adult and pediatric cooperative groups, Canadian cooperative groups, and the children’s oncology group. This collaboration played a pivotal role in the trial’s success, enabling rapid accrual and earlier achievement of primary endpoints.Elizabeth Brem emphasizes that the study achieved its primary objective by improving progression-free survival in patients with…
Shirin Attarian, MD addresses the escalating incidence of head and neck cancer and highlights that most cases, particularly oropharyngeal cancers, are driven by HPV virus infection. She discusses HPV vaccination recommendations, suggesting that individuals between 11 and 26 years old should be vaccinated, potentially starting from age 9. Vaccination for those aged 27-45 is possible after physician consultation but might be less effective due to prior exposure. Beyond 45, there are no current vaccination recommendations. Attarian explains that despite younger generations getting vaccinated, the incidence of head and neck cancer is anticipated to rise in older individuals who aren’t vaccinated.…
Nataliya Mar, MD Clinical Associate Professor in the Division of Hematology/Oncology at the University of California Irvine, provides GU ASCO Updates [2023]. What were the VESPER trial results? What were the CONTACT-03 trial results? In the case of the 68-year-old man with metastatic prostate cancer, who had initial response but then developed PSA rise, what are the key considerations when selecting treatment options for patients with somatic and germline DDR alterations? How do PARP inhibitors fit into the treatment landscape? What were the TALAPRO-2 trial results?
Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development, leading and overseeing the company’s global oncology research and development activities. In a pivotal Phase 3 randomized clinical trial, niraparib maintenance therapy has demonstrated remarkable efficacy for patients recently diagnosed with advanced ovarian cancer following initial platinum-based chemotherapy. This trial, involving 384 participants, unveiled the significant potential of niraparib in extending progression-free survival rates by a substantial 55% when compared to a placebo control group. Notably, the treatment’s effectiveness was observed across diverse patient subsets, regardless of their biomarker status or the presence of residual disease. These findings…
Pre-Roll Example
Advertising on OncologyTube For A Limited Time No Contracts! Pay As You Go! Book Now! or Contact Us for More Info or Call 1 (951) 944-2173 (Discounts available for 3, 6, and 12 month contracts) Why OncologyTube? $120 CPM the lowest in the industry (for a limited time only) 90% of our unique content is created by MD oncologists for oncologist. We work with the biggest pharmaceutical, research hospitals, and universities in the world. The most well-known oncology KOLs and researchers contribute to our platform. 10,000+ NPI-verified oncologists subscribed to our monthly eNewsletter. Thousands more worldwide. 20,500+ Social Media followers mostly…
Sanam Loghavi is Assistant Professor, Department of Hematopathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX The talk covered the emerging field of menin inhibition in AML, shedding light on its potential as a novel therapeutic strategy. The enthusiasm around this development was palpable in the presentation, reflecting the speaker’s excitement for the advancements in understanding and treating AML. Additionally, the evolving classification of AML was discussed, showcasing the dynamic nature of the field and the constant discovery of new entities within it. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US…
Yasmin Abaza, MD Assistant Professor, Medicine (Hematology and Oncology) In a captivating interview, Yasmin Abaza, MD, an esteemed Assistant Professor of Medicine at Northwestern University, delved into her research focus on Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Offering a comprehensive overview of immune cell therapies for these conditions, Dr. Abaza touched upon the historical struggles encountered in achieving successful outcomes. She candidly highlighted the limited success observed thus far while shedding light on the promising agents currently undergoing clinical trials. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU -…
Jessica Altman, MD – Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine Jessica Altman, MD, a dedicated professional at Northwestern University in Chicago, recently participated in her first conference, which proved to be a remarkable experience. At this event, she engaged in a thought-provoking debate with Dr. Dauver, focusing on the treatment of acute myeloid leukemia (AML) in adults with newly diagnosed cases. The debate centered on the comparison between triplet-based therapy and sequential therapy. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU -…
Elias Jabbour, MD – Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour, MD a dedicated professional at MD Anderson in Houston, Texas, recently presented groundbreaking insights at a conference. Formerly dire disease survival rates have been revolutionized, with ten-year survival now at an impressive ninety percent within four to five years. This transformation represents a new standard of care and a remarkable advancement for patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open…
The discussion focuses on the changing landscape of treatment for mutated acute myeloid leukemia (AML). The speaker emphasizes the significance of mutation profiles in AML patients, which can have prognostic or therapeutic implications. Poultry inhibitors are believed to have a lasting impact, with many candidates already approved or under investigation. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com The session’s agenda involves a brief introduction followed by experts discussing various aspects of…
Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell therapy for patients with relapsed refractory conditions, particularly those who have experienced multiple relapses and high tumor burdens. They highlight the success achieved with CAR T therapy, especially after treatment with Blinatumomab (Blina) and Inotuzumab Ozogamicin (I know). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Bijal Shah MD, MS,…
Charles G. Mullighan, MBBS (Hons), MSc, MD-Member, St. Jude Faculty-Deputy Director, Comprehensive Cancer Center-St. Jude Children’s Research Hospital Charles Mullighan, MD, delves into the genomic classification of Acute Lymphoblastic Leukemia (ALL) and its diagnostic approaches. He covers three main areas: B-cell ALL (BOL), implications for risk stratification and diagnosis, and insights into the classification of T-cell ALL (TOL). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com After a decade of genomic research,…
Sayeh Lavasani, MD of UCI Health gives an Update in Breast Cancer at MOASC’s Spotlight on Oncology NATALEE’s study focused on comparing adjuvant ribocyclib plus a non-steroidal AI versus an AI alone in high-risk, early-stage, hormone receptor-positive breast cancer patients. The ribocyclib was administered at a lower dose of 400 milligrams daily for three weeks on and one week off, over three years. This study showed improvements in invasive disease-free survival, as well as trends towards enhanced overall survival in a three-year follow-up. These findings suggest an additional treatment option to reduce the risk of recurrence in earlier-stage hormone-positive breast…
Regina Myers, MD, MSCE, is an instructor in the Cancer Center at Children’s Hospital of Philadelphia. Regina Myers, MD expresses gratitude for the audience’s presence and thanks the event organizers for the invitation. They introduce themselves as a pediatric oncologist speaking at an adult conference, focusing on pediatric AAA (acute lymphoblastic leukemia) and 4-1BB CAR T cell therapies. They mention the high complete response (CR) rates of up to 97% achieved with CAR19 (CAR targeting CD19), but also note the significant challenge of disease relapse after CAR19 treatment, especially in pediatric and adult patients. They attribute relapse to two main…
Shira N. Dinner, MD- Robert H Lurie Cancer Center Shira N. Dinner, MD discussed several studies focused on the treatment of acute lymphoblastic leukemia (ALL) in older adults, particularly those aged 55 and above. The presentation highlighted the challenges and outcomes associated with different treatment approaches. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTSAML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Shira N. Dinner, MDfirst emphasized the historical poor outcomes for older adults with ALL, with survival rates being notably lower compared to…
Hagop Kantarjian, MD is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center Hagop Kantarjian, MD shared exciting updates and progress in the treatment landscape. Notably, some of the predictions made back in 2010 are now proving to be successful. Initiatives like the development of the blinatumomab and inotuzumab therapies started in 2008 and by 2010, it was clear that using them as standalone treatments would not be effective, prompting a shift towards combination therapies. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTSAML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/AML-ALL EU -…
When your patient is diagnosed with a blood cancer such as chronic lymphocytic leukemia (CLL), it’s important to remember that in addition to their physical health, their mental health is a critical part of their overall well-being.1 From initial diagnosis through remission, it’s essential to ensure patients are equipped with tools and resources to help them manage the various emotions that come with a diagnosis and know how to seek professional help when needed. Many patients feel a certain stigma around mental health, so it’s important to initiate the conversation. Helping patients figure out how to create an action plan…
Nitin Jain, M.D., is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA. Nitin Jain, MD, discussed relapsed/refractory T-cell acute lymphoblastic leukemia (TLL) and the need for new therapies due to the ineffectiveness of current treatments. They highlighted studies that assessed outcomes in relapsed TLL, demonstrating a median survival of four to six months, indicating the significant unmet medical need. Nitin Jain, MD, also mentioned the criteria for defining early T-cell precursor leukemia (ETPL) based on gene expression and flow cytometry markers. They discussed different approaches for treating…
Bijal Shah, MD, MS- Hematology/Oncology- Moffitt Cancer Center Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell therapy for patients with relapsed refractory conditions, particularly those who have experienced multiple relapses and high tumor burdens. They highlight the success achieved with CAR T therapy, especially after treatment with Blinatumomab (Blina) and Inotuzumab Ozogamicin (I know). REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Bijal Shah MD, MS,…
Marina Konopleva, MD, PhD – University of Texas MD Anderson Cancer Center and Albert Einstein College of Medicine Jack and Pearl Resnick Campus The discussion revolved around patients with B-cell acute lymphoblastic leukemia (ALL) that had a gene expression signature similar to Philadelphia chromosome-positive ALL (Ph+ ALL) but lacked the characteristic genetic abnormalities. This subgroup, referred to as “PH-like ALL,” comprised around 20-30% of ALL cases, with a higher prevalence in pediatric patients. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ ML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU -…
Marlise Luskin,MD, MSCE- Medical Oncology- Dana-Farber/Mass General Brigham Hematology/Oncology Fellowship Program and education director for the adult leukemia program. The presentation focused on the use of the drug venetoclax (and its related drugs) in the treatment of acute lymphoblastic leukemia (ALL), particularly relapse refractory ALL. The speaker outlined the significant progress that has been made in the treatment of this disease, including various therapies like blinatumomab, iituzumab, and CAR T cell therapy, which have shown improvements but still leave certain subsets of patients with unmet needs. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content…
Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX Elias Jabbour, MD discussed the potential treatment options for patients facing relapsed leukemia during a medical presentation. He emphasized the importance of considering complementary strategies rather than competing ones. Dr. Jabbour advocated starting with bispecific and immunotherapy approaches before utilizing CAR T-cell therapy due to their positive impact on survival. He referred to the dire prognosis of relapsed patients, comparing it to a death sentence, and highlighted the challenges associated with traditional treatments like transplantation. REGISTER NOW TO JOIN US AT THESE UPCOMING…
IMpower010 & Atezolizumab: The trial has cemented the significance of atezolizumab in the potential treatment options for lung cancer, especially as an adjuvant in non-small cell lung cancer (NSCLC). Debate & Discourse: While promising, the broadened approval and usage of atezolizumab have sparked meaningful debate regarding its universal applicability and effectiveness. Unbiased Presentation: The oncological community must remain vigilant, ensuring that data and results are presented without bias, offering patients and practitioners clear insights into potential treatment modalities. In the vast realm of oncology, lung cancer remains a predominant concern and focus of rigorous scientific research. At the forefront of…
Ryan D. Cassaday,MD- Physician-Fred Hutch Ryan Cassaday, MD emphasizes the importance of the topic at hand and humorously compares the debate between inotuzumab and blinatumumab to choosing between seat belts and airbags, highlighting his belief that both treatments have significant roles to play. Dr. Cassaday focuses on presenting data supporting inotuzumab, specifically in the context of older adults with pH-negative B cell acute lymphoblastic leukemia (ALL). He discusses studies from MD Anderson and the German Cooperative Group that showcase the effectiveness of inotuzumab in inducing morphologic remission and achieving favorable survival curves, despite challenges such as toxicity. REGISTER NOW TO…
Anjali Advani, MD- Hematology and Medical Oncology- Cleveland Clinic Anjali Advani, MD, begins her talk by expressing gratitude for the invitation to speak. She proceeds to discuss the integration of blinatumomab into upfront therapy for acute lymphoblastic leukemia (ALL). Dr. Advani explains that blinatumomab, a bispecific antibody engaging CD3 and CD19, effectively induces T-cell proliferation and apoptosis of leukemia cells. She emphasizes blinatumomab’s advantages, including its lack of attached chemotherapy, reduced risk of complications, and potential immune effects. Dr. Advani discusses ongoing efforts to refine blinatumomab’s administration and dosage for optimal patient outcomes. REGISTER NOW TO JOIN US AT THESE…
Aaron Logan, MD, PhD- Associate Professor of Clinical Medicine, Division of Hematology/Oncology, UCSF Aaron Logan, MD PhD, conveyed his gratitude to the event organizers and acknowledged the valuable input of different perspectives at the meeting. He highlighted the critical role of assessing minimal residual disease (MRD) in leukemia treatment strategies. Drawing on data from various studies, Dr. Logan underscored how MRD presence or absence can accurately predict survival outcomes in patients undergoing therapy for leukemia. However, he also acknowledged the limitations of MRD assessments, as they don’t always perfectly predict relapse or remission. He discussed the importance of precise MRD…
Jalen Patel, MD – City of Hopeaugust 21, 2023Drawing from data provided by ASCO and Friends of Cancer Research, the study endeavors to characterize the eligibility criteria employed in advanced prostate cancer investigations. The primary objective centers on ensuring that the clinical trial parameters accurately reflect the broader population.The classification involves three distinct categories: exclusion, conditional inclusion, and instances where criteria were not reported. Upon scrutinizing the criteria of interest, the analysis reveals a predominant tendency among trials to exclude individuals with brain metastases, HIV, hepatitis B and C, as well as concurrent malignancies. The subsequent breakdown of four figures…
Akasha Dukkipati, MD at City of Hope August 21, 2023 Akasha Dukkipati, MD at City of Hope, conducted an analysis of urothelial cancer studies spanning a decade, from 2012 to 2022. The aim was to scrutinize eligibility criteria due to concerns raised by a collaborative statement from ASCO and Friends of Cancer Research. The joint statement underscored the underrepresentation of certain clinical attributes resulting from overly stringent eligibility standards in clinical trials. The physician’s team specifically focused on advanced urothelial cancer studies, examining four primary exclusion factors: concurrent malignancies, brain metastases, hepatitis B and C infections, and HIV. Their findings…
Mark Litzow, MD- Hematologist, Oncologist, Palliative Care Specialist- Mayo Clinic In a presentation delivered by Mark Litzow, MD, the speaker expresses gratitude for the invitation and acknowledges the organizers. The speaker humorously remarks that they are unsure who needs transplants nowadays. They express their intention to address the question of who needs transplantation in the first remission (CR1) and highlight the importance of relapse and its relation to transplant outcomes. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register –…
Branko Cuglievan, MD- Assistant Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX – Section Chief, Leukemia/Lymphoma, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX Branko Cuglievan, MD, expresses gratitude for being invited to an adult conference to discuss pediatric data and challenges. He addresses the differences in age distribution between acute myeloid leukemia (AML) and pediatric leukemias. Dr. Cuglievan emphasizes the lower incidence of pediatric AML cases and the struggle to enroll sufficient patients for studies due to the dispersed…
Charles G. Mullighan, MBBS (Hons), MSc, MD-Member, St. Jude Faculty-Deputy Director, Comprehensive Cancer Center-St. Jude Children’s Research Hospital Charles Mullighan, MD, expresses gratitude for the invitation to speak at the meeting and discusses the genomic classification of leukemia, particularly focusing on B-cell acute lymphoblastic leukemia (B-ALL) and T-cell acute lymphoblastic leukemia (T-ALL). He covers three main areas: B-ALL genomic classification, its implications for diagnosis and risk assessment, and recent unpublished data on T-ALL classification. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open…
Elias Jabbour, MD- Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX The talk, delivered by Elias Jabbour, MD, centers around the treatment paradigm for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), proposing a shift from traditional chemotherapy to tyrosine kinase inhibitors (TKIs) and immunotherapy. Dr. Jabbour discusses the historical use of allogeneic stem cell transplantation and its limitations. The presentation delves into data from MD Anderson and other studies, emphasizing the challenge of achieving high survival rates. The concept of complete molecular remission (CMR) is underscored, with an emphasis on early molecular response deepening.…
Wendy Stock, MD – Anjuli Seth Nayak Professor of Medicine- The University of Chicago Medicine In this presentation, Wendy Stock, MD, addresses optimizing outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Dr. Stock expresses gratitude for the opportunity and highlights the importance of such meetings, drawing from her own experience when starting her career. She discusses the positive changes in patient outcomes, particularly emphasizing minimal residual disease (MRD) eradication as a key goal. The importance of blending new therapies with older approaches and using less aggressive treatment for older patients and AYAs is mentioned. Dr. Stock…
Marina Konopleva, M.D., Ph.D.- Professor, Department of Oncology (Medical Oncology) Professor, Department of Molecular Pharmacology- Albert Einstein College of Medicine In this presentation by Marina Konopleva, MD, she covers the resistance mechanisms and potential combination strategies related to venetoclax, an AML (acute myeloid leukemia) treatment. Despite overlapping slides, she delves into the topic, shedding light on resistance challenges. Konopleva elaborates on the mechanism of action, targeting BCL-2, and its interaction with mitochondrial proteins. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/…
Tapan Kadia, MD- Professor, Department of Leukemia, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX In this presentation Tapan Kadia, MD discusses the challenge of high relapse rates despite achieving complete remissions with newer therapies. Historical attempts at maintenance therapy are reviewed, with improvements seen in relapse-free survival but not overall survival. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus Meeting 2023 aml-allus2023.md-education.com Dr. Kadia highlights the success of oral hypomethylating…
Hetty Carraway, MD- Hematology and Medical Oncology- Cleveland Clinic Hetty Carraway, MD, delivers a comprehensive discussion on immune-based and novel strategies to enhance outcomes for patients with myelodysplastic syndromes (MDS). The focus lies on unraveling the intricate relationship between the immune system and MDS pathogenesis, exploring immune interventions like immune checkpoint inhibitors (ICIs), and addressing challenges related to immune manipulation, mutational profiles, and the microenvironment. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/ MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/ Register – AML-ALL US Focus…
Andrew Artz MD- Hematologist-Oncologist- City Of Hope Andrew Artz, MD, expresses gratitude to the organizers and prior presenters, acknowledging the topic’s extensive coverage. Playfully, he considers sharing random pictures or dinner plans but proceeds to discuss his presentation’s content. He highlights the increasing use of allogeneic transplants, especially for older patients and those in first remission, attributing this rise to novel therapies. Dr. Artz emphasizes the challenge of relapse and the need to balance it against transplant-related toxicities. REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/ AML-ALL EU – Registration open…
Yasmin Abaza, MD Assistant Professor, Medicine (Hematology and Oncology) Yasmin Abaza, MD discusses advancements and challenges in the treatment of Acute Myeloid Leukemia (AML) using immunotherapies. Over the past five decades, outcomes for AML patients have improved, but long-term survival rates remain low, highlighting the need for new treatment options. Allogeneic stem cell transplantation is a potent immunotherapy for AML, particularly in patients with intermediate or adverse risk disease. The transplantation’s effectiveness lies in the donor T cell’s ability to target and destroy leukemia cells through interactions with AML cells’ molecular markers. Despite its benefits, this approach is associated with graft-versus-host…